AKT1 and metastatic neoplasm: At the time of referral to the CCTT the patient had metastatic disease to the mediastinum, bones, and liver and subsequently received experimental therapy with a mTOR inhibitor sirolimus (4 mg orally daily) in combination with a histone deacetylase inhibitor (HDAC) vorinostat (300 mg orally daily), which was matching a molecular abnormality in the PI3K/AKT/mTOR pathway (PIK3CA H1047R mutation) and attained 15% shrinkage per RECIST.